

GEN PROBE INC  
Form 8-K  
May 31, 2006

**Table of Contents**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 24, 2006**

**Gen-Probe Incorporated**

(Exact Name of Registrant as Specified in Charter)

**Delaware**

(State or Other Jurisdiction of  
Incorporation)

**001-31279**

(Commission  
File Number)

**33-0044608**

(I.R.S. Employer  
Identification No.)

**10210 Genetic Center Drive**

**San Diego, CA**

(Address of Principal Executive Offices)

**92121**

(Zip Code)

**(858) 410-8000**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 1.01 Entry into a Material Definitive Agreement

Item 9.01. Financial Statements and Exhibits

SIGNATURE

EXHIBIT 99.1

---

**Table of Contents**

**Item 1.01 Entry into a Material Definitive Agreement.**

Effective May 24, 2006, Gen-Probe Incorporated (the Company) and Diagnocure, Inc. (Diagnocure) entered into Amendment No. 1 to License, Development and Cooperation Agreement (the Amendment), amending the terms of the License, Development and Cooperation Agreement dated November 19, 2003 between the parties (the License Agreement). A copy of the License Agreement has been filed as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2003 and is described in the Company's most recent Annual Report on Form 10-K.

Pursuant to the terms of the Amendment:

- (i) Gen-Probe granted to Diagnocure exclusive rights to develop *in vivo* products for the detection or measurement of PCA3 as a marker for the diagnosis, monitoring or prognosis of prostate cancer. Diagnocure will owe Gen-Probe royalties on net sales of any such products;
- (ii) Gen-Probe granted to Diagnocure co-exclusive rights to develop fluorescence in situ hybridization products for the detection or measurement of PCA3 as a marker for the diagnosis, monitoring or prognosis of prostate cancer. Diagnocure will owe Gen-Probe royalties on net sales of any such products;
- (iii) Diagnocure will undertake over a twelve-month period the validation of genetic markers that Gen-Probe acquired under its license agreement with Corixa Corporation. Gen-Probe will make monthly payments to Diagnocure for these services; and
- (iv) Gen-Probe and Diagnocure agreed to a new regulatory timeline regarding Gen-Probe's development obligations for an *in vitro* diagnostic assay for PCA3. The new regulatory timeline may be extended only for events beyond Gen-Probe's reasonable control or those that render it in the best economic interests of the parties to defer regulatory submission. As was the case under the License Agreement prior to amendment, in the event Gen-Probe fails to meet the regulatory timeline, Gen-Probe may lose exclusivity with respect to the licensed PCA3 marker.

**Item 9.01. Financial Statements and Exhibits.**

(d) The following exhibits are filed with this Current Report:

- 99.1 Press Release dated May 30, 2006 Regarding PCA3 Prostate Cancer Collaboration between Gen-Probe and Diagnocure.
-

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 31, 2006

GEN-PROBE INCORPORATED

By: /s/ R. William Bowen  
R. William Bowen  
Vice President, General Counsel and  
Corporate  
Secretary

---

**Table of Contents**

**EXHIBITS**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release dated May 30, 2006 Regarding PCA3 Prostate Cancer Collaboration between Gen-Probe and Diagnocure